 ATLANTA, Aug. 16, 2021 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase, a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today reported financial results for the second quarter ended June 30, 2021 and highlighted recent developments. Key Business and Clinical Highlights Begin evaluation of IkT-148009 in Parkinsons patients: Following a teleconference on July 22, 2021with the U.S. Food and Drug Administration FDA, Inhibikase and the FDA agreed that the Company may begin a Phase 1b extension study to evaluate the safety, tolerability and pharmacokinetics of the Companys lead drug candidate IkT-148009 in Parkinsons patients. 